Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $222.50 short put and a strike $217.50 long put offers a potential 18.2% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $222.50 by expiration. The full premium credit of $0.77 would be kept by the premium seller. The risk of $4.23 would be incurred if the stock dropped below the $217.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 39.89 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
Mon, 10 Feb 2020 14:44:53 +0000
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
Top Stock Research Reports for Alphabet, Roche & Amgen
Fri, 07 Feb 2020 19:45:29 +0000
Top Stock Research Reports for Alphabet, Roche & Amgen
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Fri, 07 Feb 2020 15:49:03 +0000
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
Fri, 07 Feb 2020 15:28:03 +0000
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
Thu, 06 Feb 2020 20:45:08 +0000
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Related Posts
Also on Market Tamer…
Follow Us on Facebook